How Patent Expiry Lowers Trastuzumab Emtansine Prices
Trastuzumab emtansine (Kadcyla), Roche's antibody-drug conjugate for HER2-positive breast cancer, faces patent expirations starting in the late 2020s, which will enable generic and biosimilar competition. This reduces prices by allowing rivals to enter the market, cutting the branded drug's monopoly pricing. U.S. sales hit $2.3 billion in 2023, with list prices around $12,000 per month, sustained by patent protection.[1]
When Do Key Patents Expire?
Core composition-of-matter patents for Kadcyla expired in Europe in 2021, but U.S. protection lasts longer. The primary U.S. patent (US 7,416,956) covering the drug-linker conjugate expires August 28, 2027, with pediatric exclusivity extending it to February 28, 2028. Method-of-use patents extend to 2032-2035 in some cases, but generics can launch post-2028 via Paragraph IV challenges if litigation fails.[2][3] Europe saw biosimilar approvals possible after 2021, though uptake remains low.
What Happens to Prices After Expiry?
Post-patent cliffs, prices drop 30-80% within 1-2 years as generics capture 70-90% market share, based on patterns from drugs like Herceptin (trastuzumab). For Kadcyla, analysts project U.S. price erosion to $4,000-$6,000 monthly equivalents by 2030, driven by biosimilars from Sandoz, Biocon, and Samsung Bioepis, which filed ANDAs targeting 2027 launch.[2][4] Payers negotiate steeper rebates, accelerating savings.
Which Companies Are Lining Up Biosimilars?
| Company | Filing Status | Expected Launch |
|---------|---------------|-----------------|
| Sandoz (Novartis) | U.S. ANDA filed 2023 | 2027-2028 |
| Biocon/ Mylan | EU approval 2023; U.S. pending | 2028+ |
| Samsung Bioepis | U.S. ANDA 2024 | Post-2028 |
| Celltrion | Early development | 2030s |
These entrants undercut Roche's pricing, with EU biosimilars already 25-40% cheaper where available.[3][5]
Why Might Prices Not Drop as Expected?
Litigation delays are common—Roche has sued over 10 challengers, potentially pushing launches to 2030. Formulation patents (expiring 2035) could block full generics, limiting competition to partial biosimilars. Supply chain issues or manufacturing complexity for the emtansine payload may slow entries, preserving higher prices longer than for simple molecules.[2]
Impact on Patients and Payers
U.S. patients face $10,000+ out-of-pocket costs pre-expiry; post-2028, copays could halve with generics. Medicare saved $42 billion from prior oncology patent cliffs—Kadcyla could add $10-15 billion in savings by 2035. Globally, lower prices expand access in low-income countries.[1][4]
Sources
[1]: IQVIA Market Data
[2]: DrugPatentWatch.com - Kadcyla Patents
[3]: FDA Orange Book
[4]: Evaluate Pharma Forecast
[5]: EMA Biosimilar Approvals